AstraZeneca(AZN) Prnewswire·2025-02-20 10:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of AstraZeneca PLC regarding a class action lawsuit alleging that the company made materially false and misleading statements and failed to disclose significant legal risks associated with its operations in China [1][2]. Summary by Relevant Sections Allegations - The lawsuit claims that AstraZeneca engaged in insurance fraud in China, leading to increased legal exposure and the detention of its China President by law enforcement [1]. - It is alleged that AstraZeneca understated its legal risks, which could materially harm its business activities in China once revealed [1]. - The defendants' statements regarding AstraZeneca's business, operations, and prospects are claimed to be materially false and misleading [1]. Class Period and Registration - The class period for the lawsuit is from February 23, 2022, to December 17, 2024 [1]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for February 21, 2025 [2]. Next Steps for Shareholders - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible corporate behavior [3].